[2] Sabine Schnyder Ghamloush, et al. Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease. IDWeek 2024; Abstract 168....
[2] Sabine Schnyder Ghamloush, et al. Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease. IDWeek 2024; Abstract 168. 来源:《感染医线》 声明 凡署名原创的文章版权...
呼吸道合胞病毒（Respiratory Syncytial Virus，RSV）是引起包含新生儿及婴幼儿在内的5岁以下儿童肺炎和老年人肺炎的主要病原体之一，具有高度传染性和致病性。据统计，全球每年约有3300万5岁以下儿童患下呼吸道感染疾病。印度、中国、尼日利亚、巴基斯坦和印度尼西亚5个国家的RSV疾病负担约占全球的50%。早在20世纪60年...
在全球呼吸道合胞病毒(RSV)感染持续威胁公共健康的背景下,来自德国埃尔兰根-纽伦堡大学的研究团队在npj Vaccines上发表了一项突破性研究。该研究题为"Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncyt...
15. Moline HL, Tannis A, Toepfer AP, et al. Early estimate of Nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024. MMWR Morb...
1. Development of mRNA vaccines against respiratory syncytial virus (RSV) 2. Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV) 3. RSV Vaccines 2023 — Precision Vaccinations 4. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPre-F3) in Mo...
2https://www.investors.com/news/technology/gsk-stock-jumps-after-beating-pfizer-moderna-to-the-rsv-vaccine-finish-line/ 3https://us.gsk.com/en-us/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 4https://www....
Priorities for developing respiratory syncytial virus vaccines in different target populations 融合蛋白(Fusion protein, F)被宿主蛋白酶切割成F1和F2两个片段后才具有活性,能引起病毒囊膜与宿主细胞膜融合,在RSV感染引发的免疫病理中起作用,是目前抗体、疫苗及其他治疗性药物研发的热点蛋白。
[1] Clinicaltrials.gov, “Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above”. Available at: https://clinicaltrials.gov/study/NCT04886596 - last accessed: September 2024
The use of an mRNA sequence, or a composition comprising a plurality of mRNA sequences, for the preparation of a pharmaceutical composition of Respiratory Syncytial Virus (RSV), and the treatment or treatment of RSV infection with an mRNA vaccine Provision of preventive measures. SOLUTION: RSV ...